137.F Aldeyra Therapeutics Inc
- Market cap
- EUR 33.5M
- P/E
- -
- P/B
- 1.07x
- ROE
- -47.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 137.F undervalued?
Graham numberThe Graham number of Aldeyra Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aldeyra Therapeutics Inc fundamental analysis
No fundamental analysis for Aldeyra Therapeutics Inc yet.
Aldeyra Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-…
Full company profileAldeyra Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aldeyra Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | - | -22.5M | -39.7M | -56.5M | -34.7M | -56.2M | -62.7M | -42.8M | -60.1M | -35.3M | -18.0M |
| EBITDA | - | -22.2M | -38.7M | -61.4M | -36.1M | - | -60.1M | -35.2M | -53.7M | -31.7M | -15.9M |
| Net Income | - | -22.3M | -38.9M | -60.8M | -37.6M | -57.8M | -62.0M | -37.5M | -55.9M | -33.8M | -16.9M |
| EPS | - | -1.17 | -1.48 | -2.12 | -0.97 | -0.99 | -1.06 | -0.63 | -0.94 | -0.56 | -0.28 |
| Balance Sheet | |||||||||||
| Total Assets | - | 44.2M | 95.1M | 75.5M | 83.4M | 233M | 181M | 148M | 105M | 72.1M | 43.4M |
| Total Liabilities | - | 4.57M | 8.47M | 27.4M | 23.8M | 27.4M | 30.3M | 28.5M | 33.6M | 27.8M | 8.16M |
| Shareholders' Equity | - | 39.6M | 86.6M | 48.1M | 59.5M | 206M | 151M | 120M | 71.0M | 44.3M | 35.2M |
| Cash & Short-term Investments | - | 20.0M | 47.4M | 44.4M | 77.9M | 230M | 144M | 143M | 54.5M | 70.0M | 41.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -15.1M | -19.2M | -29.9M | -45.0M | -37.5M | -42.6M | -56.6M | -30.3M | -43.2M | -33.3M | -18.4M |
| Capital Expenditure | 0.00 | 24.8K | 263K | 9.53K | 0.00 | 7.81K | 16.3K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -19.2M | -30.1M | -45.0M | -37.5M | -42.6M | -56.7M | -30.3M | -43.2M | -33.3M | -18.5M |
| Ratios | |||||||||||
| ROE | - | -56.4% | -44.9% | -126.5% | -63.1% | -28.1% | -41.1% | -31.3% | -78.7% | -76.5% | -47.9% |
| ROA | - | -50.6% | -40.9% | -80.5% | -45.1% | -24.8% | -34.2% | -25.3% | -53.4% | -47.0% | -38.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Aldeyra Therapeutics Inc dividends
Aldeyra Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Aldeyra Therapeutics Inc
- Insiders 3.60%
- Institutions 60.71%
- Public & others 35.69%
- Shares outstanding 60.4M
- Free float 48.9M
Aldeyra Therapeutics Inc company profile
- Company name
- Aldeyra Therapeutics Inc
- Ticker
- 137.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- 131 Hartwell Avenue, Lexington, MA, United States, 02421
- Phone
- 781 761 4904
- Website
- aldeyra.com
About Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Aldeyra Therapeutics Inc management
4- Dr. Todd C. Brady M.D., Ph.D.CEO, President & Director · born 1972
- Mr. Michael AlfieriHead of Finance and Principal Financial & Accounting Officer · born 1965
- David BurkeHead of Investor Relations
- Dr. Adam LazorchakDirector of Translational Sciences & Non-Clinical Development